A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
The aim is to strengthen industry-academia cooperation
Subscribe To Our Newsletter & Stay Updated
